A Phase III, multi-center, randomized, double-blind, non-inferiority study of Solithromycin versus Levofloxacin in patients with community-acquired pneumonia

Trial Profile

A Phase III, multi-center, randomized, double-blind, non-inferiority study of Solithromycin versus Levofloxacin in patients with community-acquired pneumonia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Solithromycin (Primary) ; Levofloxacin
  • Indications Community-acquired pneumonia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 23 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top